2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2744

Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment

Vasculitis Poster III: Other Vasculitis Syndromes

9:00AM-11:00AM: Abstract Number: 2481

Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars

9:00AM-11:00AM: Abstract Number: 2736

Long-Term Survival in Systemic Necrotizing Vasculitides

Vasculitis Poster III: Other Vasculitis Syndromes

9:00AM-11:00AM: Abstract Number: 2432

Longitudinal Changes in Gene Expression Associated with Disease Activity during Pregnancy and Post-Partum Among Women with Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2131

Longitudinal Cohort Study of Anti-PM/Scl Myositis Patients: Mild Muscle and Lung Involvement with Prominent Perivascular Inflammation

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2264

Low Educational Attainment Is Associated with Poor Patient Status in Rheumatoid Arthritis (RA) or Osteoarthritis (OA) at the Initial Rheumatology Visit, with Remarkably Similar Patterns in Either Diagnosis

Patient Outcomes, Preferences, and Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2033

Low Health Literacy Does Not Impact Adherence to Hydroxychloroquine in Patients with Systemic Lupus

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 2373

Low or High BMI Negatively Impacts RA Disease Activity in an Asian RA Cohort

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2675

Lung Transplant Trends in Patients’ with Systemic Sclerosis Using UNOS (United Network Organ Sharing) Database from 2000-2014

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2642

Lupus Serum Induces Glomerular Endothelial Cell Neutrophil Adhesion in Association with Soluble Mediators of Chemotaxis and Adhesion

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1999

Magnetic Resonance Imaging of Skeletal Muscles in Patients with Dermatomyositis and Polymyositis: Novel and Distinctive Characteristic Findings

Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2238

Mapping Paindetect, a Neuropathic Pain Screening Tool, to Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Patients with Rheumatoid Arthritis: Developing a Neuropathic Pain Scale As a Measure of Treatment Outcome

Patient Outcomes, Preferences, and Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2420

Mass Cytometry Analysis of CD4+ T Cells in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2115

Mast Cell Activation Features in Ehlers-Danlos/Joint Hypermobility Patients: A Retrospective Analysis in Light of an Emerging Disease Cluster

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2231

MCC22, a Novel Compound That Targets Both CCR5 and Mu Opioid Receptors, Is Highly Effective in Treating Inflammatory Arthritis Pain

Pain – Basic and Clinical Aspects Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].